|
|
GEO help: Mouse over screen elements for information. |
|
Status |
Public on May 15, 2012 |
Title |
Molecular profiles of pyramidal cell dysfunction in the superior temporal cortex in schizophrenia |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
Gray matter volume in the cerebral cortex has been consistently found to be decreased in patients with schizophrenia. The superior temporal gyrus (STG) is one of the cortical regions that exhibit the most pronounced volumetric reduction. This reduction is generally thought to reflect, at least in part, decreased number of synapses; the majority of these synapses are believed to be furnished by glutamatergic axon terminals onto the dendritic spines on pyramidal neurons. Pyramidal neurons in the cerebral cortex exhibit layer-specific connectional properties, providing neural circuit structures that support distinct aspects of higher cortical functions. For instance, dendritic spines on pyramidal neurons in layer 3 of the cerebral cortex are targeted by both local and long-range glutamatergic projections in a highly reciprocal fashion. Synchronized activities of pyramidal neuronal networks, especially in the gamma frequency band (i.e. 30-100 Hz), are critical for the integrity of higher cortical functions. Disturbances of these networks may contribute to the pathophysiology of schizophrenia by compromising gamma oscillation. This concept is supported by the following postmortem and clinical observations. First, the density of dendritic spines on pyramidal neurons in layer 3 of the cerebral cortex, including the STG, have been shown to be significantly decreased by 23-66% in subjects with schizophrenia. Second, consistent with these findings, the average somal area of these pyramidal cells is significantly smaller. Third, we have recently found that, in the prefrontal cortex, the density of glutamatergic axonal boutons, of which dendritic spines are their major targets, was significantly decreased by as much as 79% in layer 3 (but not layer 5) in subjects with schizophrenia. Finally, an increasing number of clinical studies have consistently demonstrated that gamma oscillatory synchrony is profoundly impaired in patients with schizophrenia. Furthermore, gamma impairment has been linked to the symptoms and cognitive deficits of the illness and the severity of these symptoms and deficits have in turn been associated with the magnitude of cortical gray matter reduction. Taken together, understanding the molecular underpinnings of pyramidal cell dysfunction will shed important light onto the pathophysiology of cortical dysfunction of schizophrenia. In order to gain insight into the molecular determinants of pyramidal cell dysfunction in schizophrenia, we combined LCM with Affymetrix microarray and high-throughput TaqMan®-based MegaPlex qRT-PCR approaches, respectively, to elucidate the alterations in messenger ribonucleic acid (mRNA) and microRNA (miRNA) expression profiles of these neurons in layer 3 of the STG. We found that transforming growth factor beta (TGFβ) and BMP (bone morphogenetic proteins) signaling pathways and many genes that regulate extracellular matrix (ECM), apoptosis and cytoskeleton were dysregulated in schizophrenia. In addition, we identified 10 miRNAs that were differentially expressed in this illness; interestingly, the predicted targets of these miRNAs included the dysregulated pathways and gene networks identified by microarray analysis. Together these findings provide a neurobiological framework within which we can begin to formulate and test specific hypotheses about the molecular mechanisms that underlie pyramidal cell dysfunction in schizophrenia.
|
|
|
Overall design |
Gene epxression microarray from RNA isolated from pyramidal cells in layer III of the STG from 9 normal controls and 9 subjects with schizophrenia. There was no significant difference between diagnosis groups for age, sex, and post mortem interval (PMI).
|
|
|
Contributor(s) |
Pietersen CY, Kim SS, Lim MP, Mauney SA, Rooney RJ, Chen J, Stephens RM, Goldstein JM, Petryshen TL, Seidman LJ, Shenton ME, McCarley RW, Sonntag K, Woo TW |
Citation(s) |
24702465 |
|
Submission date |
May 14, 2012 |
Last update date |
Nov 06, 2018 |
Contact name |
Sarah Mauney |
E-mail(s) |
[email protected]
|
Phone |
6178552079
|
Fax |
6178553479
|
Organization name |
McLean Hospital
|
Lab |
Laboratory for Cellular Neuropathology
|
Street address |
115 Mill St.
|
City |
Belmont |
State/province |
MA |
ZIP/Postal code |
02478 |
Country |
USA |
|
|
Platforms (1) |
GPL1352 |
[U133_X3P] Affymetrix Human X3P Array |
|
Samples (18)
|
|
Relations |
BioProject |
PRJNA166867 |
Supplementary file |
Size |
Download |
File type/resource |
GSE37981_RAW.tar |
82.1 Mb |
(http)(custom) |
TAR (of CEL, CHP) |
Processed data included within Sample table |
Processed data provided as supplementary file |
|
|
|
|
|